News & Innovations

News and innovations published by German exhibitors

  back to overview

Novel Small Molecule Targeting Huntington’s Disease Is Ready for Clinical Trials

Since 2019 Bicoll GmbH has supported Galyan Bio Inc. in developing and optimizing an orally available small molecule for Huntington’s Disease Target. Clinical trials are scheduled for 2022.

Planegg / Martinsried (Germany) – Bicoll, an expert in synthesizing new and relevant small molecules as starting points for accelerated drug development, announced today its supporting role in the development of novel drug candidates for Huntington’s disease in collaboration with Galyan Bio.

Further reading

Exhibitor: Bicoll GmbH


We only use functionally necessary cookies and the web analysis tool Matomo in order to optimally design and continuously improve our website for you. By continuing to use our website, you agree to this. Further information and an objection possibility can be found here: Data protection